Douglas Drysdale

Douglas L.
Drysdale is currently Chief Executive Officer & Director at Pernix Manufacturing LLC, Chief Executive Officer at Cybin IRL Ltd., Executive Chairman at BetterLife Pharma, Inc. starting in 2026, Director at SpineThera, Inc. since 2022, and Director at Adelia Therapeutics, Inc. Former roles include Chief Executive Officer at Norwich Pharmaceuticals, Inc., Chairman, President & Chief Executive Officer at Pernix Therapeutics Holdings, Inc. from 2014 to 2016, Chief Executive Officer at Cybin, Inc. from 2020 to 2025, Chief Executive Officer at Alvogen Group, Inc. from 2008 to 2013, Chief Executive Officer at Clarmin Explorations, Inc., President & Chief Executive Officer at Tedor Pharma, Inc. from 2017 to 2020, Chief Executive Officer at Cybin Corp., Director at Cypress Pharmaceuticals, Inc., Principal at Forest Laboratories, Inc., Vice President at Zoetis Products LLC, Vice President-Mergers & Acquisitions at Actavis Group ehf from 2004 to 2008, and Executive Vice President-Corporate Development at Alkensa, Inc. Education includes an undergraduate degree from the University of East Anglia, conferred in 1992.